Materiały źródłowe

• #1 Thrombocytosis and Thrombocytopenia Care In NJ, CT, and MD| Regional Cancer Care Associates

  https://www.regionalcancercare.org/hematology/benign-hematology-services/thrombocytosis-and-thrombocytopenia/

  Thrombocytosis is a condition that causes the body to produce an unusually high number of blood platelets. This may lead to more serious problems, such as a stroke or heart attack. The condition most commonly affects older individuals, and may or may not require treatment depending on its severity. There are two main types of thrombocytosis: […] Primary thrombocytosis: This type of thrombocytosis occurs for no apparent reason. The bone marrow creates abnormal and abundant blood cells, making it difficult for the body to form clots after a cut. This may be due to a gene mutation that was not inherited but developed after birth. […] Secondary thrombocytosis: This type of thrombocytosis develops in the setting of other medical issues, such as surgery, trauma, blood loss, inflammatory conditions, cancer, infections, or iron deficiency.

• #1 Thrombocytosis and Cancer Risk: Management in Primary Care | MDedge

  https://community.the-hospitalist.org/internalmedicinenews/article/271594/hematology/thrombocytosis-and-cancer-risk-management-primary-care

  Louisa has an unexplained thrombocytosis. How do we manage this in primary care? Thrombocytosis is generally defined as a raised platelet count over 450. Importantly, thrombocytosis is a common incidental finding in around 2% of those over 40 years of age attending primary care. Reassuringly, 80%-90% of thrombocytosis is reactive, secondary to acute blood loss, infection, or inflammation, and the majority of cases resolve within 3 months. […] Although most cases are reactive, clinical guidance (for example, NICE suspected cancer guidance in the UK and Scottish suspected cancer guidance in Scotland) reminds us that unexplained thrombocytosis is a risk marker for some solid-tumor malignancies. […] However, thrombocytosis should not be used as a stand-alone diagnostic or screening test for cancer, or indeed to rule out cancer. Instead, unexplained thrombocytosis should prompt us to think cancer.

• #1

  https://www.rgare.com/knowledge-center/article/reactive-thrombocytosis-a-benign-entity

  Thrombocytosis, a condition defined as having a platelet count of more than 450,000 per microliter of blood (450 x 109/L), can be either physiologic in nature or due to primary or secondary causes. […] Secondary or reactive thrombocytosis (RT) is far more prevalent than primary or clonal thrombocytosis, and the presence of comorbid conditions in RT, a transient rise in platelets, and lack of genetic mutations favor a secondary etiology. […] Clinical manifestations of RT can range from no symptoms (most common) to acute thrombosis (rare), and elevated platelet counts may also be a predictor of underlying disease and of mortality. […] Therefore, it is essential for an underwriter to identify RT, as RT is not always a benign entity, which means outcomes can vary. […] RT is typically a clinically silent and transient condition. No clear correlation exists between symptoms and platelet counts; even patients with platelet counts of 1 million/microL due to RT are usually asymptomatic.

• #1 Thrombocytosis and Thrombocytopenia Care In NJ, CT, and MD| Regional Cancer Care Associates

  https://www.regionalcancercare.org/hematology/benign-hematology-services/thrombocytosis-and-thrombocytopenia/

  Many people with thrombocytosis do not experience symptoms. When symptoms do arise, people with thrombocytosis may experience: Tingling or numb feet and hands, Swelling in the feet and hands, Headaches, Weakness, Dizziness, Chest pain, Intestinal or stomach bleeding. […] In many cases, people with mild thrombocytosis or thrombocytopenia will not need treatment. If the patient has an underlying medical condition, symptoms typically resolve once that problem is under control, with platelet levels returning to normal. However, if the condition worsens or becomes severe, patients may need one or more of the following treatments: Medication, Platelet removal, Blood transfusion, Plasma exchange, Spleen-removal surgery. […] The hematologists, medical oncologists, and other health care professionals of Regional Cancer Care Associates serve people across New Jersey, Connecticut, Maryland, and the Washington, D.C. area. With a dedication to providing compassionate and patient-centered care, our team can assist patients with blood disorders and other conditions.

• #1 How I Work up the Patient with Thrombocytosis – The ASCO Post

  https://ascopost.com/issues/march-15-2012/how-i-work-up-the-patient-with-thrombocytosis/

  Thrombocytosis is defined as a platelet count greater than 400 109/L. In managing the patient with thrombocytosis, one must first distinguish reactive from primary thrombocytosis. The presence of acute or subacute infection, a connective tissue disorder, vasculitis, hemolysis, active bleeding, recent surgery, history of splenectomy, or iron deficiency anemia favors the diagnosis of reactive thrombocytosis. The presence of chronic thrombocytosis, thrombohemorrhagic complications, microvascular symptoms, or splenomegaly favors the diagnosis of primary thrombocytosis. However, clinical impression often requires confirmation through laboratory testing, which is also necessary to distinguish among the different causes of primary thrombocytosis (including essential thrombocythemia). […] In addition to morphologic analysis, bone marrow examination allows the performance of cytogenetic studies and special immunohistochemical stains. For example, the detection of a clonal cytogenetic abnormality is diagnostic of primary thrombocytosis. However, although some causes of primary thrombocytosis are always associated with an abnormal cytogenetic lesion (for example, chronic myelogenous leukemia [CML]), less than 5% of patients with essential thrombocythemia have detectable cytogenetic abnormalities.

• #1

  https://www.rgare.com/knowledge-center/article/reactive-thrombocytosis-a-benign-entity

  The risk of thrombotic complications from RT is considered to be low, occurring in only 1.6% of patients in one large case series, with all thrombotic events identified as venous and occurring in patients with other risk factors, such as a postoperative state or with underlying malignancy. […] Interestingly, RT in patients with iron deficiency anemia has been associated with a twofold thrombosis risk compared with patients with iron deficiency anemia alone. […] Given that the overall risk of thrombosis is considered to be low in RT, treatment with anti-platelet therapy such as aspirin is usually not indicated. Still, treatment can be considered for patients with platelets of 1 million/microL with complications of thrombocytosis, or for patients at risk of developing such complications. […] RT is associated with higher mortality in acutely ill patients. […] RT is an independent predictor of mortality in asymptomatic elderly individuals. […] Elevated platelets are associated with worse outcomes in individuals hospitalized with COVID-19.

• #1 How I Work up the Patient with Thrombocytosis – The ASCO Post

  https://ascopost.com/issues/march-15-2012/how-i-work-up-the-patient-with-thrombocytosis/

  The first step in approaching a patient with thrombocytosis is to entertain the possibility of reactive thrombocytosis. It is worth reiterating the value of mutation screening for JAK2V617F in distinguishing essential thrombocythemia from reactive thrombocytosis but not from other myeloproliferative neoplasms. In addition, rare cases of genetically defined essential thrombocythemia (eg, activating mutation of MPL) have been described and must be kept in mind while evaluating a patient with either a lifelong or family history of thrombocytosis. […] The second step in evaluating a patient with thrombocytosis is to confirm the diagnosis of essential thrombocythemia with a bone marrow examination and exclude the possibility of other myeloid disorders, including prefibrotic primary myelofibrosis. Although detailed analysis of megakaryocyte morphology might assist in distinguishing CML (dwarf megakaryocytes and not too many clusters) from essential thrombocythemia (giant megakaryocytes with cluster formation), cytogenetic studies or FISH for BCR/ABL1 should accompany bone marrow examination to rule out the possibility of CML. […] Mild reticulin fibrosis (grades 1 or 2) is detected in approximately 14% of patients with essential thrombocythemia at diagnosis and does not portend an unusual outcome. Clonal cytogenetic lesions in essential thrombocythemia are detected in 5% of cases and are nonspecific.

• #1 Thrombocytosis (Guidelines) | Right Decisions

  https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/haematology/thrombocytosis-guidelines/

  Thrombocytosis is a common finding and is a frequent cause of referral for further investigation. […] The most common secondary (or reactive) causes of thrombocytosis are infection, inflammation, iron deficiency, tissue damage, haemolysis, severe exercise, malignancy, hyposplenism and other causes of an acute phase response. […] Management in Primary Care includes checking ferritin, CRP, blood film, and excluding other causes of inflammation, including infection, malignancy, surgery. […] Further investigation will be directed by secondary care after referral or consultation. […] Management in Secondary Care is as per primary care guidance. […] Note that molecular testing may be best deferred to community testing in order to exclude reactive thrombocytosis in the context of illness. […] Escalation criteria include associated thrombosis or bleeding.

• #1 Essential Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK539709/

  Essential thrombocytosis is characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow. […] This activity describes the presentation, cause, management, and potential complications of essential thrombocytosis and reviews the role of the interprofessional team in caring for patients with this disease. […] The goal of the treatment of essential thrombocytosis is to prevent vascular complications such as thrombotic and hemorrhagic events; this is because thrombosis and hemorrhage are the leading causes of morbidity and mortality. […] Treatment and management of essential thrombocytosis require an interprofessional team approach involving physicians, nursing staff, and pharmacy, working together to achieve optimal patient outcomes.

• #1 Secondary Thrombocytosis Treatment & Management: Medical Care, Long-Term Monitoring

  https://emedicine.medscape.com/article/206811-treatment

  The primary treatment of secondary thrombocytosis (reactive thrombocytosis) should address the underlying cause of the thrombocytosis. For example, iron supplementation may normalize platelet counts in patients with thrombocytosis secondary to inflammatory bowel disease. […] In general, no treatment is indicated to directly reduce the platelet count. […] However, for patients with platelet counts in excess of 1,000,000/L, daily low-dose aspirin may be considered to minimize the rare development of stroke or thrombosis. […] In patients with secondary thrombocytosis (reactive thrombocytosis) for whom the causal condition has not been identified, maintain careful outpatient monitoring with physical examination and routine laboratory tests to exclude the development of an occult disorder (eg, malignancy).

• #1 Thrombocytosis: Symptoms, Causes, and Treatment | Doctor

  https://patient.info/doctor/thrombocytosis

  Thrombocytosis is defined as a platelet count above the upper limit of the normal range (450 x 109/L in adults). […] This article aims to outline diagnosis, investigation and management of patients with thrombocytosis and to highlight possible complications. […] Management requires an assessment of the individual’s risk and, where possible, taking remedial action. […] Patients with essential thrombocythaemia are considered at high risk of thrombosis if they are older than 60 years or have a previous history of thrombosis and at high risk of bleeding if platelet counts are above 1,500 x 109/L. […] Patients with low-risk essential thrombocythaemia are usually managed with low-dose aspirin, whereas treatment of high-risk essential thrombocythaemia is based on the use of cytoreductive therapy, with hydroxyurea as the drug of choice and interferon alfa (IFN-) being reserved for young patients or pregnant women.

• #1 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  Our caring team of Mayo Clinic experts can help you with your thrombocytosis-related health concerns […] Thrombocytosis care at Mayo Clinic […] You might need to take daily, low-dose aspirin to help thin your blood if you’re at risk of blood clots. Don’t take aspirin without checking with your health care team. […] Your doctor might prescribe platelet-lowering drugs such as hydroxyurea (Droxia, Hydrea), anagrelide (Agrylin) or interferon alfa (Intron A). […] In emergencies, platelets can be filtered from your blood with a machine. This procedure is called plateletpheresis. The effects are only temporary. […] For thrombocytosis, questions to ask include: What treatment do you recommend? What follow-up care will I need? […] Your doctor is likely to ask you questions, such as: Do you have a family history of high platelet counts?

• #1 Thrombocytosis: Symptoms, Causes, and Treatment | Doctor

  https://patient.info/doctor/thrombocytosis

  In patients with low risk, simple observation may be justified. […] Where there are symptoms of microvascular occlusion such as erythromelalgia, low-dose aspirin may be very effective. […] In high-risk patients, including those with very high platelet counts, the platelets must be reduced. […] Possible treatments include hydroxyurea, anagrelide or IFN-. […] When there are acute complications, plateletpheresis may achieve a rapid decrease in platelet count. […] If patients require elective surgery and are not at very low risk, cytoreductive therapy should be employed to reduce the risk of both thrombosis and haemorrhage. […] Hydroxyurea is an antimetabolite that acts as a false precursor and is a very effective treatment. […] Anagrelide is an imidazoquinazoline drug that inhibits platelet aggregation but it also decreases platelet production.

• #1 16.4 Thrombocytopenia – Medical-Surgical Nursing | OpenStax

  https://openstax.org/books/medical-surgical-nursing/pages/16-4-thrombocytopenia

  Nursing care for the patient with thrombocytopenia focuses on avoiding bleeding complications, creating a safe environment, and supporting overall patient well-being. Nurses should monitor laboratory tests and vital signs, administer medication, take safety precautions, and educate the patient about their condition. Effective communication and collaboration between the patient and members of the health-care team are crucial in optimizing treatment of this disorder and increasing overall quality of life for everyone affected by it. […] Evaluation of interventions for thrombocytopenia requires an ongoing and methodological process to assess their efficacy and assess any changes that implemented measures have on the patients hemostasis levels. The nurse should keep the following points foremost in mind: The primary focus of evaluation is to monitor the patients platelet counts to detect improvements or declining trends. It is also important to evaluate the patients response to medications. The nurse should be aware of side effects and adverse reactions to prescribed medications, which may include nausea, vomiting, and clot formation. Documentation is essential to visualize trends in vital signs, blood components, and clotting times. Indications that the patient is improving include normalization of vital signs and blood tests showing stabilizing or improving platelet levels and decreasing clotting times.

• #1 Essential thrombocythemia | University of Iowa Health Care

  https://uihc.org/health-topics/essential-thrombocythemia

  Aspirin is sometimes prescribed by a doctor to relieve discomfort at the tips of fingers and toes. […] In addition to the treatment recommended by your doctor, there are steps you can take to help reduce or prevent the symptoms of ET: […] It is important that you be alert for any change or increase in symptoms. If this occurs, it may mean that you need additional or different treatments, and you should contact your doctor right away. […] ET requires regular appointments with your doctor. He or she will want to discuss your symptoms and do periodic blood counts to evaluate your response to treatment. […] Prognosis depends upon the symptoms you may have, your age, and the treatment you receive. Some patients may only need minimal care and observation, while other patients may require more intensive treatment.

• #1 Thrombocytosis – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/symptoms-causes/syc-20378315

  Thrombocytosis care at Mayo Clinic […] Your risk of pregnancy complications may be reduced with regular checkups and medication, so be sure to have your doctor regularly monitor your condition. […] Connect with others like you for support and answers to your questions in the Blood Cancers Disorders support group on Mayo Clinic Connect, a patient community.

• #1 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia

  Is a rare blood disease in which the bone marrow produces too many platelets. High numbers of platelets may lead to a thrombus, a blood clot that forms in a blood vessel. This can cause serious health problems such as a stroke, heart attack or pulmonary embolism. […] ET does not generally shorten life expectancy. However, medical supervision is important to prevent or treat thrombosis, a serious complication that can affect vital organs such as the brain or the heart. Also, for untreated pregnant patients with ET, there is a risk to the survival of the fetus. […] The mutated cell leads to uncontrolled blood cell production, especially platelets – although red cells and white cells are usually affected as well. […] This results in the release of too many platelets into the blood. […] When platelets are present in very high numbers they may not function normally and may cause a blockage in blood vessels, known as a „thrombus.” Less often, a high number of platelets can also cause bleeding problems.

• #2 Approach to the patient with thrombocytosis – UpToDate

  https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis

  Approach to the patient with thrombocytosis […] This topic discusses our approach to the adult or child with unexplained thrombocytosis. […] Clinical manifestations and diagnosis of specific causes of thrombocytosis are discussed separately. […] Thrombocytosis refers to an increased platelet count which, in this review, is ≥450,000/microL (≥450 x 10^9/L).

• #2 Thrombocytosis (Guidelines) | Right Decisions

  https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/haematology/thrombocytosis-guidelines/

  Thrombocytosis is a common finding and is a frequent cause of referral for further investigation. […] The most common secondary (or reactive) causes of thrombocytosis are infection, inflammation, iron deficiency, tissue damage, haemolysis, severe exercise, malignancy, hyposplenism and other causes of an acute phase response. […] Management in Primary Care includes checking ferritin, CRP, blood film, and excluding other causes of inflammation, including infection, malignancy, surgery. […] Further investigation will be directed by secondary care after referral or consultation. […] Management in Secondary Care is as per primary care guidance. […] Note that molecular testing may be best deferred to community testing in order to exclude reactive thrombocytosis in the context of illness. […] Escalation criteria include associated thrombosis or bleeding.

• #2 Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data | British Journal of General Practice

  https://bjgp.org/content/67/659/e405

  Thrombocytosis (raised platelet count) is an emerging risk marker of cancer, but the association has not been fully explored in a primary care context. […] To examine the incidence of cancer in a cohort of patients with thrombocytosis, to determine how clinically useful this risk marker could be in predicting an underlying malignancy. […] Thrombocytosis is a risk marker of cancer in adults; 11.6% and 6.2% cancer incidence in males and females, respectively, is worthy of further investigation for underlying malignancy. […] Thrombocytosis has previously been identified as a marker of some types of cancer (lung, colorectal, renal, and uterine), but not all sites have been studied, and the effects of age, sex, and change in platelet count over time have not been examined. […] The positive predictive value of thrombocytosis is 11.6% (95% confidence interval [CI] = 11.0 to 12.3) for males and 6.2% (95% CI = 5.9 to 6.5) for females.

• #2

  https://www.rgare.com/knowledge-center/article/reactive-thrombocytosis-a-benign-entity

  Thrombocytosis, a condition defined as having a platelet count of more than 450,000 per microliter of blood (450 x 109/L), can be either physiologic in nature or due to primary or secondary causes. […] Secondary or reactive thrombocytosis (RT) is far more prevalent than primary or clonal thrombocytosis, and the presence of comorbid conditions in RT, a transient rise in platelets, and lack of genetic mutations favor a secondary etiology. […] Clinical manifestations of RT can range from no symptoms (most common) to acute thrombosis (rare), and elevated platelet counts may also be a predictor of underlying disease and of mortality. […] Therefore, it is essential for an underwriter to identify RT, as RT is not always a benign entity, which means outcomes can vary. […] RT is typically a clinically silent and transient condition. No clear correlation exists between symptoms and platelet counts; even patients with platelet counts of 1 million/microL due to RT are usually asymptomatic.

• #2 Thrombocytosis and Cancer Risk: Management in Primary Care | MDedge

  https://community.the-hospitalist.org/internalmedicinenews/article/271594/hematology/thrombocytosis-and-cancer-risk-management-primary-care

  If thrombocytosis is unexplained or not resolving, consider checking ferritin levels to exclude iron deficiency. Consider checking C-reactive protein (CRP) levels to exclude any inflammation, and also consider checking a blood film to exclude any hematologic disorders, in addition, of course, to more detailed history-taking and examination to elicit any red flags. […] We can also consider a JAK2 gene mutation test, if it is available to you locally, or a hematology referral if we suspect a myeloproliferative disorder. […] Subsequent to this, and again using our clinical judgment, we then need to exclude the LEGO-C cancers. Consider urgent chest x-ray to exclude lung cancer or pelvic ultrasound in women to exclude endometrial cancer. […] Alongside these possible investigations, as always, we should safety-net appropriately within agreed timeframes and check for resolution of the thrombocytosis according to the condition being suspected. Remember, most cases resolve within 3 months. […] I appreciate these scenarios are not always this straightforward, but I wanted to outline what investigations and referrals we may need to consider in primary care if we encounter an unexplained high platelet count.

• #2 Essential thrombocythemia | University of Iowa Health Care

  https://uihc.org/health-topics/essential-thrombocythemia

  Essential thrombocythemia (ET), or primary thrombocythemia, is a disorder that causes the overproduction of platelets in the blood. […] The primary goal of treatment is to lower the number of platelets in your blood. […] In some patients, the best treatment is to monitor the disorder for any increase in symptoms and have a doctor do periodic blood counts. This may be the only management ever needed. […] Medications used to lower the number of platelets in the blood including hydroxyurea and anagrelide. Your doctor will determine which medication is best for you. […] Biological therapy, or immunotherapy, uses substances made naturally in the body to bolster your own immune response. Alpha-interferon is a natural substance often used to treat ET. […] During plateletpheresis, a special machine filters the excess platelets out of the blood. This is usually done only when the platelet count is very high, and the effect is temporary.

• #2 Secondary Thrombocytosis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/30100

  Secondary thrombocytosis, also known as reactive thrombocytosis, is characterized by an abnormally high platelet count due to underlying events, infections or diseases, or certain medications. […] Although secondary thrombocytosis is typically benign, the underlying causes such as malignancy, connective tissue disorders, and chronic infections can be associated with an increased risk of adverse outcomes. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications.

• #2 Secondary Thrombocytosis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/30100

  Platelets act as acute-phase reactants, and secondary thrombocytosis can occur due to acute underlying infections, tissue damage, chronic inflammatory disorders, and malignancies. […] For patients with secondary thrombocytosis where the underlying cause remains unidentified, a comprehensive evaluation is necessary to rule out occult disorders such as malignancies.

• #2 Thrombocytosis: Symptoms, Causes, and Treatment | Doctor

  https://patient.info/doctor/thrombocytosis

  In patients with low risk, simple observation may be justified. […] Where there are symptoms of microvascular occlusion such as erythromelalgia, low-dose aspirin may be very effective. […] In high-risk patients, including those with very high platelet counts, the platelets must be reduced. […] Possible treatments include hydroxyurea, anagrelide or IFN-. […] When there are acute complications, plateletpheresis may achieve a rapid decrease in platelet count. […] If patients require elective surgery and are not at very low risk, cytoreductive therapy should be employed to reduce the risk of both thrombosis and haemorrhage. […] Hydroxyurea is an antimetabolite that acts as a false precursor and is a very effective treatment. […] Anagrelide is an imidazoquinazoline drug that inhibits platelet aggregation but it also decreases platelet production.

• #2 Essential thrombocythemia | University of Iowa Health Care

  https://uihc.org/health-topics/essential-thrombocythemia

  Aspirin is sometimes prescribed by a doctor to relieve discomfort at the tips of fingers and toes. […] In addition to the treatment recommended by your doctor, there are steps you can take to help reduce or prevent the symptoms of ET: […] It is important that you be alert for any change or increase in symptoms. If this occurs, it may mean that you need additional or different treatments, and you should contact your doctor right away. […] ET requires regular appointments with your doctor. He or she will want to discuss your symptoms and do periodic blood counts to evaluate your response to treatment. […] Prognosis depends upon the symptoms you may have, your age, and the treatment you receive. Some patients may only need minimal care and observation, while other patients may require more intensive treatment.

• #2 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia

  Is a rare blood disease in which the bone marrow produces too many platelets. High numbers of platelets may lead to a thrombus, a blood clot that forms in a blood vessel. This can cause serious health problems such as a stroke, heart attack or pulmonary embolism. […] ET does not generally shorten life expectancy. However, medical supervision is important to prevent or treat thrombosis, a serious complication that can affect vital organs such as the brain or the heart. Also, for untreated pregnant patients with ET, there is a risk to the survival of the fetus. […] The mutated cell leads to uncontrolled blood cell production, especially platelets – although red cells and white cells are usually affected as well. […] This results in the release of too many platelets into the blood. […] When platelets are present in very high numbers they may not function normally and may cause a blockage in blood vessels, known as a „thrombus.” Less often, a high number of platelets can also cause bleeding problems.

• #3 Thrombocytosis | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/thrombocytosis

  Platelets are parts of the blood that help form blood clots. Thrombocytosis (throm-boe-sie-TOE-sis) is a disorder in which your body produces too many platelets. […] It’s important to determine whether it’s reactive thrombocytosis or essential thrombocythemia to choose the best treatment options. […] Treatment for this condition depends on the cause. […] People with this condition who have no signs or symptoms usually don’t need treatment. You might need to take daily, low-dose aspirin to help thin your blood if you’re at risk of blood clots. […] Your doctor might prescribe platelet-lowering drugs such as hydroxyurea (Droxia, Hydrea), anagrelide (Agrylin) or interferon alfa (Intron A). […] In emergencies, platelets can be filtered from your blood with a machine. This procedure is called plateletpheresis. The effects are only temporary.

• #3 Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data | British Journal of General Practice

  https://bjgp.org/content/67/659/e405

  This strongly suggests that cancer should be considered when a result is received showing thrombocytosis, even if cancer was not initially suspected. […] This analysis found that lung and colorectal cancers are more likely to be diagnosed in patients with thrombocytosis than in the general population, and breast and prostate cancers are less likely. […] In at least one-third of all lung and colorectal cancer patients, thrombocytosis could potentially have triggered investigation in a patient hitherto not meeting current recommendations for referral.

• #3 Essential thrombocythemia | University of Iowa Health Care

  https://uihc.org/health-topics/essential-thrombocythemia

  Essential thrombocythemia (ET), or primary thrombocythemia, is a disorder that causes the overproduction of platelets in the blood. […] The primary goal of treatment is to lower the number of platelets in your blood. […] In some patients, the best treatment is to monitor the disorder for any increase in symptoms and have a doctor do periodic blood counts. This may be the only management ever needed. […] Medications used to lower the number of platelets in the blood including hydroxyurea and anagrelide. Your doctor will determine which medication is best for you. […] Biological therapy, or immunotherapy, uses substances made naturally in the body to bolster your own immune response. Alpha-interferon is a natural substance often used to treat ET. […] During plateletpheresis, a special machine filters the excess platelets out of the blood. This is usually done only when the platelet count is very high, and the effect is temporary.

Zobacz więcej